Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon

Rheumatology

Volumn 39, Issue 10, 2000, Pages 1132-1138

  Hayoz, D ^a   Bizzini, G ^a   Noel B ^a   Depairon, M ^a   Burnier, M ^a   Fauveau, C ^b   Rouillon, A ^b   Brouard, R ^b   Brunner, H R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SANOFI   (France)

Author keywords

Human; Raynaud's phenomenon; Receptor antagonist; SR 49059; Vasopressin

Indexed keywords

PLACEBO; RELCOVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; WATER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FINGER; HAND; HEART RATE; HUMAN; LOW TEMPERATURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SIDE EFFECT; SKIN TEMPERATURE; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; TIME; WATER IMMERSION;

EID: 0033783025     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.10.1132     Document Type: Article

References (44)

1. On local asphyxia and symmetrical gangrene of the extremities
2. Role of digital artery adrenoceptors in Raynaud's disease
3. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease
4. Adrenoceptors in Raynaud's disease
5. Raynaud's phenomenon
6. Cold-induced changes in plasma norepinephrine, epinephrine and dopamine concentrations in patients with Raynaud's phenomenon
7. Cutaneous responses to endothelin-1 and histamine in patients with vibration white finger
8. Digital cutaneous vascular responses to histamine and neuropeptides in Raynaud's phenomenon
9. On the nature of Raynaud's phenomenon: The role of histamine
10. Pharmacotherapy of Raynaud's phenomenon
11. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin
12. Effect of magnesium sulfate infusion on circulating levels of noradrenaline and neuropeptide-Y-like immunoreactivity in patients with primary Raynaud's phenomenon
13. Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis
14. Successful treatment of esophageal dysmotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Increase in plasma VIP concentration
15. Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease
16. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon
17. Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: The role of endothelin
18. Wholebody cooling increases plasma endothelin-1 levels in women with primary Raynaud's phenomenon
19. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon
20. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon
21. Controlled multicenter double-blind trial on nicardipine in the treatment of primary Raynaud phenomenon
22. Possible erythemalgia-like syndrome associated with nifedipine in a patient with Raynaud's phenomenon
23. Rational use of calcium-channel antagonists in Raynaud's phenomenon
24. Heterogeneous vascular response to vasopressin: Radial artery versus forearm blood flow
25. Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor
26. Vasopressin induces opposite changes in blood flow in the skin and the muscular circulation
27. Heterogeneity of the aggregation response of human platelets to arginine vasopressin
28. Biochemical and pharmacological properties of SR 49059, a new, potent, non-peptide antagonist of rat and human vasopressin V1a receptors
29. Raynaud's disease: A critical review of minimal requisites for diagnosis
30. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders
31. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans
32. Clinical studies of the vibration syndrome using a cold stress test measuring finger temperature
33. Plasma vasopressin in rats: Effect of sodium, angiotensin, and catecholamines
34. Blockade of the vascular effect of vasopressin in patients with mild essential hypertension
35. Different factors influencing the expression of Raynaud's phenomenon in men and women
36. The occurrence of Raynaud's phenomenon in a general population: The Framingham study
37. Geographic variation in the prevalence of Raynaud's phenomenon: A 5 region comparison
38. Symptoms of Raynaud's phenomenon in an inner-city African-American community: Prevalence and self-reported cardiovascular comorbidity
39. Biphasic forearm vascular responses to intraarterial arginine vasopressin
40. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers
41. Arginine vasopressin attenuates phenylephrine-induced forearm vasoconstriction in men
42. Reproducibility of cold provocation in patients with Raynaud's phenomenon
43. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon